Enterofuril (nifuroxazide) capsules 200 mg. №8

Description

Enterofuril №8 Composition
active substance: nifuroxazide;

1 hard capsule contains nifuroxazide 200 mg;

other components: corn starch, sucrose, powdered cellulose, magnesium stearate. Enterofuril 200 mg gelatin capsule contains: titanium dioxide (E 171), yellow iron oxide (E 172), gelatin.

Enterofuril №8 Dosage form
The capsules are hard.

Basic physical and chemical properties: hard oblong gelatin capsules, composed of a body and a lid, ocher-yellow (Enterofuril 200 mg), filled with granulate or slightly compressed yellow granulate, which disintegrates under light pressure. Capsule size 0 (Enterofuril 200 mg).

Pharmacotherapeutic group
Antidiarrheal drugs used to treat infectious and inflammatory bowel diseases. Antimicrobial agents for the treatment of intestinal infections. Nifuroxazide. ATX code A07A X03.

Pharmacodynamics
Nifuroxazide is an antimicrobial drug derived from nitrofuran. The mechanism of action is not fully understood. The antimicrobial and antiparasitic properties of nifuroxazide are possibly due to the presence of an amino group. Local activity and lack of penetration into organs and tissues of the body determines the uniqueness of nifuroxazide in comparison with other nitrofuran derivatives, since there is no systemic effect of this antidiarrheal drug. Effective against gram-positive and gram-negative bacteria: Streptococcus pyogenes, Staphylococcus aureus, E. coly, Salmonellae, Shigellae.

Pharmacokinetics
After oral administration, nifuroxazide is practically not absorbed from the gastrointestinal tract and does not enter the organs and tissues, more than 99% of the drug remains in the intestine. Biotransformation of nifuroxazide occurs in the intestine, about 20% of the amount taken is excreted unchanged. Nifuroxazide and its metabolites are excreted in the feces. The rate of elimination of the drug depends on the amount of drug taken and the motility of the gastrointestinal tract. In general, the withdrawal of nifuroxazide is slow; it remains in the gastrointestinal tract for a long time.

In therapeutic doses, nifuroxazide practically does not suppress the normal intestinal microflora, does not entail the emergence of resistant microbial forms, as well as the development of cross-resistance of bacteria to other antibacterial drugs. The therapeutic effect is achieved from the first hours of treatment.

Enterofuril №8 Indications
Acute diarrhea of ​​infectious etiology.

Contraindications
Hypersensitivity to nifuroxazide, other 5-nitrofuran derivatives or other components of the drug.

Interaction with other medicinal products and other forms of interaction
Nifuroxazide is not recommended to be used simultaneously with sorbents, drugs that contain alcohol, drugs that can cause antabuse reactions, and drugs that suppress the central nervous system.